This page shows the latest Evrysdi news and features for those working in and with pharma, biotech and healthcare.
Another competitor in the SMA market – Roche’s Evrysdi (risdiplam) – was recently approved in the US for the treatment of SMA in adults and children aged two months and older, following ... Roche has priced Evrysdi by patient weight, with a maximum
Evrysdi becomes the third drug approved to treat the condition and is the first that can be administered orally. ... Roche has priced Evrysdi by patient weight, with a maximum cost of $340, 000 per year, which is much less than its competitors.
Outcome of FDA review due by 24 May
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...